NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癌症疫苗的全球市場:成長,趨勢,及預測(2019年∼2024年)

Cancer Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 391386
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
癌症疫苗的全球市場:成長,趨勢,及預測(2019年∼2024年) Cancer Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
出版日期: 2021年04月21日內容資訊: 英文 115 Pages
簡介

全球癌症疫苗市場在2019年∼2024年間,預測將以16.7%的年複合成長率增長。

本報告提供全球癌症疫苗市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各技術·治療方法·用途·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各技術
    • 重組癌症疫苗
    • 全細胞癌症疫苗
    • 病毒載體·DNA癌症疫苗
    • 其他(樹突狀細胞,抗原等)
  • 各治療法
    • 預防疫苗
    • 治療疫苗
  • 各用途
    • 前列腺癌
    • 子宮頸癌
    • 其他(肝癌,皮膚癌等)
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Aduro BioTech, Inc.
    • Astellas Pharma, Inc.
    • AstraZeneca PLC
    • Bristol-Myers Squibb
    • Dendreon
    • GlaxoSmithKline
    • Merck & Co., Inc.
    • OSE Immunotherapeutics
    • Sanofi

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 51683

The cancer vaccines market is projected to register a CAGR of 13.24% during the forecast period, with a revenue of approximately USD 4,825.61 million in 2020 and expected to reach USD 10,175.41 million by 2026.

Due to the sudden outbreak of the COVID-19, the cancer vaccine market observed a significant setback in terms of growth. As the COVID-19 cases were rising, globally the healthcare systems had shifted their focus in curbing the disease thereby resulting in the delay of prevention, diagnosis, and treatment of other chronic conditions like cancer. Thus, a negative impact is expected on the cancer vaccine market currently. However, in the forthcoming years, the market is expected to gain its momentum owing to the relaxation of restrictions and bouncing back of the R&D activities and clinical trials related to cancer vaccines.

Certain factors that are driving the Cancer vaccine market's growth include the increasing number of cancer cases, rising investments and government funding in the development of cancer vaccines, and technological developments in cancer vaccines.

As per the International Agency for Research on Cancer (IARC), in December 2020, globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. The IARC estimated that in 2020, the prevalence of cancer rose to 19.3 million cases and 10 million cancer deaths in year 2020, which was around 18 million cancer cases around the world in 2018. With this growing burden, the prevention of cancer is one of the most significant challenges. The cancer vaccines play a vital role in the maintenance of the immune system, as they are considered to be biological response modifiers. These cancer vaccines target the infectious agents that may cause cancer, through the production of the antibodies.

Cancer vaccines are considered to be a new therapy and are not popular, as compared to the other alternative therapeutic drugs. However, cancer vaccines have shown great potential in both preventive and therapeutic ways. Moreover, As number of cases of cancer are increasing, the development of new cancer vaccines is also increasing for treatment and prevention of disease. In 2019, Sanofi invested EUR 80 million in BioNTech, a German biotech company, for the development of messenger RNA cancer vaccine for the treatment of solid tumors.

However,the stringent regulatory issues, along with longer timelines in manufacturing of vaccines along with the availability alternative therapies, act as major hindering factors, in terms of the global cancer vaccines market's growth.

Key Market Trends

Recombinant Cancer Vaccines are Expected to a Hold Significant Market Share in the Cancer Vaccines Market

A recombinant vaccine is a vaccine produced through recombinant DNA technology. This includes DNA encoding an antigen, which stimulates an immune response into mammalian cells, expressing the antigen in these cells and then purifying it from them. Many different viruses have been genetically modified to express tumour-associated antigens (TAA) for intramuscular or subcutaneous injection.

Poxviruses have several beneficial features as vectors for cancer vaccines, including broad cell tropism, potent immunogenicity, and pre-existing neutralizing immunity, only in those patients who received the vaccinia virus (the smallpox vaccine). Vaccinia virus, fowlpox virus, and canarypox virus have been investigated clinically for cancer vaccination.

Furthermore, numerous studies are being conducted in the field of viral recombinant cancer vaccines, which may reap positive results in future, primarily related to cancer vaccination. This is expected to aid the market's growth. For instance, In July 2019, Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company collaborated and issued Innovate UK grant to CHAIN Biotechnology Ltd and the University of Oxford to develop OVM-100, a recombinant overlapping peptide (ROP) HPV vaccine targeted at cervical cancer.

However, the recent COVID 19 pandemic has posed a significant negative impact on the respective segment by delaying the development activities of recombinant cancer vaccines.

North America Dominates the Market Over the Forecast Period

North America is expected to grow due to the high prevalence of cancer, along with developed healthcare infrastructure in the region. The United States has a better healthcare infrastructure than most developed countries. The National Cancer Institute (NCI) stated that the national spending on cancer care is expected to reach USD 156 billion by 2020.

According to the estimates of the GLOBOCAN, in 2020, an estimated 1,95,499 new cases of cancer were diagnosed in Mexico, and 90,222 people died from the disease. The rising number of cancer cases are creating opportunities for market players.

The major market players are focusing on R&D activities to bring new and reliable treatments to the market. In December 2020, Anixa Biosciences a San Jose, California based biotech company in partnership with Cleveland Clinic received USFDA investigational new drug application for its new breast cancer vaccine technology developed by Cleveland Clinic immunologist Dr Vincent Tuohy, and his research team to start the first human clinical trials.

Providence Therapeutics is a Toronto based clinical stage biotechnology company that develops cancer vaccines for human use. Currently company is developing a personalized mRNA cancer vaccine designed to generate strong T cell responses that aim to kill cancer cells and destroy tumors in ovarian cancer, breast cancer and brain cancer.

Competitive Landscape

The global cancer vaccines market is consolidated and consists of a few major players. Market players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, mergers, and acquisitions. Companies, like AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline, Roche, Merck & Co. Inc., OSE Immunotherapeutics, Sanofi, and Moderna among others, hold substantial shares in the cancer vaccines market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Cancer
    • 4.2.2 Rising Investments and Government Funding in the Development of Cancer Vaccines
    • 4.2.3 Technological Developments in Cancer Vaccines
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Guidelines and Longer Timelines Required for Manufacturing Process
    • 4.3.2 Presence of Alternative Therapies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 Recombinant Cancer Vaccines
    • 5.1.2 Whole-cell Cancer Vaccines
    • 5.1.3 Viral Vector and DNA Cancer Vaccines
    • 5.1.4 Other Technologies (Dendritic Cells, Antigen, etc.)
  • 5.2 By Treatment Method
    • 5.2.1 Preventive Vaccine
    • 5.2.2 Therapeutic Vaccine
  • 5.3 By Application
    • 5.3.1 Prostate Cancer
    • 5.3.2 Cervical Cancer
    • 5.3.3 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Anixa Biosciences, Inc.
    • 6.1.2 AstraZeneca PLC
    • 6.1.3 Bristol Myers Squibb Company
    • 6.1.4 F. Hoffmann-La Roche AG (Genentech)
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 OSE Immunotherapeutics
    • 6.1.8 Sanofi SA
    • 6.1.9 Dendreon Pharmaceuticals LLC.
    • 6.1.10 Moderna, Inc.
    • 6.1.11 Vaccitech Limited
    • 6.1.12 ProvidenceTherapeutics
    • 6.1.13 eTheRNA immunotherapies

7 MARKET OPPORTUNITIES AND FUTURE TRENDS